Condition

B-cell Acute Lymphoblastic Leukemia clinical trials and research

• 38Clinical trials
• 1New in 30 days
• 26Countries

Newest B-cell Acute Lymphoblastic Leukemia clinical trials

All recruiting trials (38)

• CD19 and CD22 in vivo CAR-T therapy for relapsed/refractory B-ALL

  This study tests a one-of-a-kind in vivo CAR-T treatment that targets CD19 first and then CD22 in adults with relapsed or refractory B-ALL to see if it is safe and possibly effective.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07927816

• GI001 CAR-T for relapsed or refractory B-cell NHL and B-ALL

  This treatment study tests GI001, an in vivo CAR-T therapy, to see if it is safe and helpful for adults with relapsed or refractory B-cell NHL or B-ALL.

  Recruiting Early Phase 1 Hematology department of the 920th hospital · Yunnan, Kunming · NCT07862010

• Umbilical Cord Blood CAR-T Cells Targeting CD19 and CD22 for relapsed/refractory B-ALL

  This phase 1 study tests whether dual-target cord blood-derived CAR-T cells against CD19 and CD22 are safe and tolerable in adults with relapsed or refractory B-cell ALL.

  Recruiting Phase 1 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07838714

• Dual-target CD22/CD19 CAR-T consolidation after first remission in high-risk B-ALL

  This test will try a dual-target CD22/CD19 CAR-T cell treatment as consolidation for patients with high-risk B-cell acute lymphoblastic leukemia who are in their first remission.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07575971

• CD22/CD19 CAR-T consolidation for adults with standard-risk B-ALL

  This study will try dual-target CD22/CD19 CAR-T cell therapy as a consolidation treatment for adults with standard-risk B-cell acute lymphoblastic leukemia who are in first remission.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07575919

• MK-1045 versus blinatumomab for relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia

  This trial will test whether MK-1045 helps people with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia more than the standard immunotherapy blinatumomab.

  Recruiting at 30 sites Phase 2/3 Merck Sharp & Dohme LLC · Toronto, Ontario and 29 other locations · NCT07570173

• SYNCAR-100 for adults with relapsed or refractory B‑cell acute lymphoblastic leukemia

  This study will try SYNCAR-100, a circRNA-based injectable therapy, in adults with CD19-positive relapsed or refractory B‑cell acute lymphoblastic leukemia to see if it is safe and helps control the disease.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT07429461

• Vaccine protection after blinatumomab in children with B-ALL

  This project will see if children and young adults (ages 1–21) with B-cell acute lymphoblastic leukemia who received blinatumomab keep protective immunity from routine childhood vaccines and whether revaccination restores immunity when levels are low.

  Recruiting at 2 sites Arkansas Children's Hospital Research Institute · Little Rock, Arkansas and 1 other locations · NCT07422337

• Fludarabine dosing for children and young adults with B-cell acute lymphoblastic leukemia

  This trial will test whether pharmacokinetic (PK)-targeted fludarabine dosing before tisagenlecleucel CAR T-cell therapy helps children and young adults with relapsed or refractory B‑cell ALL more than standard fludarabine dosing.

  Recruiting at 7 sites Phase 3 Memorial Sloan Kettering Cancer Center · New York, New York and 7 other locations · NCT07223021

• Evaluating a new CAR T-cell therapy for patients with relapsed B-cell cancers

  This study is testing a new CAR T-cell therapy to see if it can help adults with relapsed B-cell cancers like leukemia and lymphoma feel better and live longer.

  Recruiting Phase 1 University of Kansas Medical Center · Westwood, Kansas · NCT06879340

• Inotuzumab Ozogamicin + Venetoclax + Dexamethasone (IoVeX) for relapsed B-cell ALL

  This trial will test whether the drug combination Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone (IoVeX) is safe and well tolerated in children and adults with relapsed B-cell acute lymphoblastic leukemia.

  Recruiting Phase 1 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT06863259

• Using donor-derived CAR-T cells to treat relapsed B-cell leukemia

  This study is testing a new type of CAR-T cell therapy made from donor cells to see if it can help people with relapsed B-cell leukemia feel better.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT06793241

• Combining a new cell therapy with stem cell transplantation for leukemia patients in remission

  This study is testing a new cell therapy combined with stem cell transplantation to see if it can help teenagers and adults with a type of leukemia who are in remission but still have some cancer cells left.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06608732

• Evaluating CAR-T cell therapy with or without stem cell transplantation for relapsed B-cell leukemia

  This study tests if adding a stem cell transplant after CAR-T cell therapy can help young people with relapsed B-cell leukemia live longer and feel better.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06581081

• Treatment of B-cell Acute Lymphoblastic Leukemia with YK012

  This study is testing a new treatment called YK012 to see if it can safely help people with B-cell acute lymphoblastic leukemia fight their cancer.

  Recruiting at 12 sites Phase 1/2 Excyte Biopharma Ltd · Guangzhou, Guangdong and 11 other locations · NCT06580301

• New CAR T-cell therapy for pediatric B-ALL

  This study is testing a new type of CAR T-cell therapy for children with tough-to-treat B-cell leukemia to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT06559189

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Using blinatumomab with autologous stem cell transplant for B-cell leukemia treatment

  This study is testing a new treatment for adults with B-cell leukemia that combines a drug called blinatumomab with a stem cell transplant to see if it helps improve their chances of recovery.

  Recruiting Phase 1 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06507514

• Treatment with Inaticabtagene Autoleucel for Adult Leukemia Patients

  This study is testing a new treatment called Inaticabtagene Autoleucel to see if it helps adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia feel better and stay safe during their recovery.

  Recruiting at 10 sites Juventas Cell Therapy Ltd. · Beijing, Beijing Municipality and 9 other locations · NCT06450067

• Zilovertamab Vedotin for Pediatric and Young Adult Cancer Patients

  This study is testing a new drug called zilovertamab vedotin to see if it can help kids and young adults with certain types of cancer that haven't responded to other treatments.

  Recruiting at 70 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 70 other locations · NCT06395103

• Using decitabine, venetoclax, and blinatumomab for maintenance therapy in B-ALL patients after stem cell transplant

  This study is testing a combination of three medications to see if they can help people with B-cell acute lymphoblastic leukemia stay in remission after a stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06393985

• CIK cell therapy for relapsed or refractory B‑cell acute lymphoblastic leukemia with early CAR‑T dysfunction

  We are testing whether giving regular or mRNA‑modified CIK cells helps children and young adults with relapsed or refractory B‑cell ALL who show early CAR‑T cell exhaustion stay free of relapse or disease progression longer.

  Recruiting Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06389305

• Comparing CD19 and CD22 CAR T-cell therapies for treating relapsed B-ALL

  This study is testing whether giving patients with relapsed B-cell Acute Lymphoblastic Leukemia two different types of CAR T-cell therapies one after the other works better than just one type followed by a stem cell transplant.

  Recruiting Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06343090

• Donor-derived CD19 CAR T cells with allo‑HSCT followed by donor-derived CD22 CAR T cells for relapsed/refractory B‑ALL

  This study tests donor-derived CD19 CAR T cells followed by an allogeneic stem‑cell transplant and sequential donor-derived CD22 CAR T cells in children and adolescents (1–18 years) with relapsed or refractory CD19+/CD22+ B‑ALL who cannot provide their own cells.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06326008

• CLIC-2201 treatment for relapsed B cell cancers

  This study is testing a new CAR-T cell therapy called CLIC-2201 to see if it can help people with relapsed B cell cancers feel better and improve their treatment outcomes.

  Recruiting at 7 sites Phase 1 British Columbia Cancer Agency · Calgary, Alberta and 6 other locations · NCT06208735

• Bispecific CAR-T cell therapy for relapsed B-cell cancers

  This study is testing a new type of CAR-T cell therapy that targets two cancer markers to see if it helps people with relapsed B-cell cancers feel better and have better outcomes.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT06081478

• Using donor-derived CAR T cells to treat pediatric B-cell leukemia

  This study is testing a new type of CAR T cell treatment made from donor cells to see if it can help children and young adults with hard-to-treat B-cell leukemia.

  Recruiting Phase 1 Bambino Gesù Hospital and Research Institute · Rome, Italy · NCT06080191

• Testing VIP943 for advanced blood cancers

  This study is testing a new drug called VIP943 to see if it can safely help people with advanced blood cancers like leukemia and myelodysplastic syndrome who have run out of other treatment options.

  Recruiting at 5 sites Phase 1 Vincerx Pharma, Inc. · Birmingham, Alabama and 4 other locations · NCT06034275

• Combining two CAR T cell therapies for treating advanced B-ALL in children

  This study is testing if giving two types of CAR T cell therapies together can help children and young adults with advanced B-cell leukemia who haven't responded to other treatments.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT05674175

• Treatment of relapsed or refractory B-cell leukemia in children and adolescents

  This study is testing a new treatment called CNCT19 to see if it can help children and teenagers with relapsed or hard-to-treat B-cell leukemia feel better and live longer.

  Recruiting at 6 sites Phase 1/2 Juventas Cell Therapy Ltd. · Hefei, Anhui and 8 other locations · NCT05667506

• CAR T-cell therapy for relapsed B-lineage leukemia and lymphoma

  This study is testing if a new CAR T-cell therapy can be safely given to patients with relapsed B-lineage leukemia and lymphoma to see how well it works.

  Recruiting at 2 sites Phase 2 KK Women's and Children's Hospital · Singapore and 1 other locations · NCT05648019

• Caloric restriction and exercise to improve chemotherapy effectiveness in B-ALL

  This study is testing if eating less and following a personalized exercise plan during chemotherapy can help older kids and young adults with B-cell Acute Lymphoblastic Leukemia respond better to treatment and avoid gaining weight.

  Recruiting at 15 sites Phase 2 Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California and 15 other locations · NCT05082519

• Blinatumomab treatment after specific stem cell transplant for high-risk leukemia

  This study is testing if a new treatment using blinatumomab after a special type of stem cell transplant can help children and young adults with high-risk leukemia stay in remission and live longer.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04746209

• New CAR-T therapy for pediatric B-cell leukemia and lymphoma

  This study is testing a new CAR-T therapy for children with tough-to-treat B-cell leukemia and lymphoma to see if it can help them get better and have more treatment options.

  Recruiting Phase 1/2 University of Colorado, Denver · Aurora, Colorado · NCT04544592

• Evaluating safety of tisagenlecleucel that doesn't meet specifications

  This study is testing a special treatment called tisagenlecleucel to see if it is safe and works for kids and young adults with a type of leukemia and adults with a type of lymphoma, even if the treatment doesn't meet standard quality checks.

  Recruiting at 49 sites Phase 3 Novartis · Hamilton, Ontario and 54 other locations · NCT04094311

• Evaluating the safety of azer-cel in patients with relapsed/refractory B-cell cancers

  This study is testing a new treatment called azer-cel to see if it is safe and effective for adults with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 15 sites Phase 1 Imugene Limited · Tampa, Florida and 14 other locations · NCT03666000

• Combination treatment for BCR-ABL positive B-cell leukemia and chronic myeloid leukemia

  This study is testing a new combination treatment for people with BCR-ABL positive B-cell leukemia or chronic myeloid leukemia to see if it helps them feel better and works well with existing medications.

  Recruiting at 4 sites Phase 1 Dana-Farber Cancer Institute · Chicago, Illinois and 3 other locations · NCT03595917

• Eliminating total body irradiation for young patients with B-cell leukemia

  This study is testing a new treatment plan for children and young adults with B-cell leukemia to see if they can safely skip total body radiation before their stem cell transplant.

  Recruiting at 24 sites Phase 2 Pediatric Transplantation & Cellular Therapy Consortium · Birmingham, Alabama and 23 other locations · NCT03509961

Related topics

Quick answers

How many B-cell Acute Lymphoblastic Leukemia clinical trials are recruiting right now?

38, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in China (18 trials), United States (15 trials), Canada (4 trials), Netherlands (3 trials), Italy (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 12, Phase 1/2: 8, Phase 2: 7, Early Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →